ADMA Biologics, Inc., a biopharmaceutical firm, has taken on the task of developing, producing, and marketing specialty plasma-derived biologics. The firm, which operates both in the United States and internationally, concentrates on treating immune deficiencies and infectious diseases. BIVIGAM, an intravenous immune globulin drug for primary humoral immunodeficiency (PI), ASCENIV, also an IVIG drug for PI, and Nabi-HB, used for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B, are all among the medications that the company offers. ADMA Biologics, Inc. also has a pipeline of plasma-derived therapeutics in the works, which includes products designed to treat and prevent S. pneumonia infection for an immunoglobulin. Moreover, the company has plasma collection facilities that it operates. Drug wholesalers, independent distributors, specialty pharmacies, and other alternate site providers are among the sales channels used by the corporation to sell its products. In 2004, ADMA Biologics, Inc. was created and it is currently headquartered in Ramsey, New Jersey.
ADMA Biologics's ticker is ADMA
The company's shares trade on the NASDAQ stock exchange
They are based in Ramsey, New Jersey
There are 51-200 employees working at ADMA Biologics
It is admabiologics.com
ADMA Biologics is in the Healthcare sector
ADMA Biologics is in the Biotechnology industry
The following five companies are ADMA Biologics's industry peers: